We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Teijin Pharma and Sato Pharmaceutical jointly announced on June 26 that they will begin marketing Bonalfa High Lotion 20 mu-g/g (tacalcitol), an ethical agent for treating psoriasis vulgaris, on June 27.
At least $15.8 million has been used by the Angolan government and its partners in the "Viva a Vida com Saúde" ("Enjoy a Healthy Life") campaign intended to vaccinate 3.6 million children under age 5.
New York-based Pfizer has informed Neurocrine Biosciences it is terminating a collaborative agreement to develop and promote the insomnia drug indiplon, the company announced June 22, just days after it was revealed the drug may need to undergo more clinical trials.
Germany-based Merck KGaA will suspend development of a new treatment for Parkinson's disease after clinical trials failed to confirm the results of earlier studies, the company said.
Novartis Pharma Japan has filed a new drug application (NDA) for Xolair for subcutaneous injection, its proprietary agent for treating bronchial asthma (BA), with Japan's Ministry of Health, Labor and Welfare.
Pharmaceutical company Lupin Ltd today said it has recieved the final approval from USFDA to market its Abbreviated New Drug Application (ANDA) of hypertension medicine Quinapril in US.
Novartis' generic unit, Sandoz Inc, filed a complaint in a US court against a decision granting Teva Pharmaceutical Industries Ltd a 180-day exclusivity deal for Teva's generic version of Merck's cholesterol-fighting drug Zocor.
Genaera Corporation today announced issuance by the United States Patent and Trademark Office of patent number 7,056,698 entitled "Nucleic Acids Encoding Interleukin-9 Receptor Variants."
Galapagos NV, a genomics-based drug discovery company, announced today that its service division BioFocus DPI has signed collaborations with Indus Biosciences, a subsidiary of CiVentiChem LLC in Hyderabad, and ProCitius, a division of Sanmar Speciality Chemicals Limited in Chennai, both providers of integrated chemistry services to life sciences companies.
Endo Pharmaceuticals Inc., a wholly owned subsidiary of Endo Pharmaceuticals Holdings Inc., today announced that the U.S. Food and Drug Administration (FDA) has granted final approval of the company's New Drug Applications (NDAs) for its extended- release and immediate-release formulations of oxymorphone hydrochloride.